Effect of sex in systemic psoriasis therapy: Differences in prescription, effectiveness and safety in the BIOBADADERM prospective cohort
EntityUAM. Departamento de Medicina
PublisherUppsala: Medical journals Sweden AB
10.2340/00015555-3711Acta Dermato-Venereologica 101.1 (2021): adv00354
ISSN0001-5555 (print); 1651-2057 (online)
Funded byThe BIOBADADERM project is promoted by the Fundación Piel Sana Academia Española de Dermatología y Venereología, which receives financial support from the Spanish Medicines and Health Products Agency (Agencia Española de Medicamentos y Productos Sanitarios) and from pharmaceutical companies (Abbott/Abbvie, Pfizer, MSD, Novartis, Lilly, Janssen and Almirall).
Subjectsgender; sex; gender bias; sex bias; psoriasis; biological therapy; drug prescription; drug safety; Medicina
Note"Artículo escrito por un elevado número de autores, solo se referencian el que aparece en primer lugar, el nombre del grupo de colaboración, si le hubiere, y los autores pertenecientes a la UAM".
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.
The effect of sex on systemic therapy for psoriasis has not been well studied. The aim of this study was to analyse a large multicentre Spanish cohort of 2,881 patients with psoriasis (58.3% males), followed from January 2008 to November 2018, to determine whether sex influences prescription, effectiveness of therapy, and the risk of adverse events. The results show that women are more likely than men to be pre-scribed biologics. There were no differences between men and women in effectiveness of therapy, measur-ed in terms of drug survival. Women were more likely to develop adverse events, but the difference in risk was small and does not justify different management. Study limitations include residual confounding and the use of drug survival as a proxy for effectiveness.
Google Scholar:Hernández-Fernández, Carlos Pelayo - Daudén Tello, Esteban - BIOBADADERM Study Group
This item appears in the following Collection(s)
Showing items related by title, author, creator and subject.
Factors associated with receiving biologics or classic systemic therapy for moderate-to-severe psoriasis: Evidence from the PSONET registries
Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document
Thrombospondin-1/CD47 interaction regulates Th17 and treg differentiation in psoriasis